Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature

References

• Grateau G, Duruoz MT. Autoinflammatory conditions: when to suspect? How to treat? Best Pract Res Clin Rheumatol. 2010;24:401-11.
   Google Scholar
• Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351:659–64.
   Google Scholar
• Berkun Y, Ben-Chetrit E, Klar A. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever—are they more frequent? Semin Arthritis Rheum. 2007;36:316–21.
   Google Scholar
• Brik R, Shinawi M, Kasinetz L, Gershoni-Baruch R. The mus-culoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum. 2001;44:1416–9.
   Google Scholar
• Younes M, Kahn MF, Meyer 0. Hip involvement in patients with familial Mediterranean fever. A review of ten cases. Joint Bone Spine. 2002;69:560–5.
   Google Scholar
• Incel NA, Saracoglu M, Erdem HR. Seronegative spond-yloarthropathy of familial Mediterranean fever. Rheumatol Int. 2003;23:41–3.
   Google Scholar
• Kaushik P, el-Sobkie NI, Shehab D, Malaviya AN. Familial Mediterranean fever with HLA B-27 positive ankylosing spon-dylitis in a young Armenian man. Clin Exp Rheumatol. 1999;17: 387–8.
   Google Scholar
• Livneh A, Langevitz P, Zemer D, et al. The changing face of familial Mediterranean fever. Semin Arthritis Rheum. 1996;26:612–27.
   PubMed Web of Science ®Google Scholar
• Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R. Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy. 2005;4:117–24.
   Google Scholar
• Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of familial Mediterranean fever and its effect on sec-ondary AA amyloidosis. J Clin Rheumatol. 2004;10:134–7.
   PubMed Web of Science ®Google Scholar
• Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum. 2005;53:146–7.
   PubMed Web of Science ®Google Scholar
• Yuksel S, Yalcinkaya F, Acar B, Ozcakar ZB, Ozturk B, Ekim M. Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford). 2006;45:1307–8.
   PubMed Web of Science ®Google Scholar
• Sakallioglu 0, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol. 2006;24:435–7.
   Google Scholar
• Ozgocmen S, Ozcakar L, Ardicoglu 0, Kocakoc E, Kaya A, Kiris A. Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol. 2006;25: 83–7.
   Google Scholar
• Seyahi E, Ozdogan H, Celik S, Ugurlu S, Yazici H. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol. 2006;24:S99–103.
   Google Scholar
• Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A. Familial Mediterranean fever successfully treated with etaner-cept. J Clin Rheumatol. 2007;13:38–40.
   Google Scholar
• Bodur H, Seckin U, Eser F, Ergul G, Seckin S. Coexistence of familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy. Rheumatol Int. 2008;29:107–10.
   Google Scholar
• Kaya S, Kaptanoglu E, Elden H, Hizmetli S. Coexistence of familial Mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept. Intern Med. 2010;49:619–22.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Matsuda M, Tazawa K, Shimojima Y, Ikeda S. Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever. Intern Med. 2007;46:1247–9.
   Google Scholar
• Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease. Clin Rheumatol. 2010;29: 209–10.
   Google Scholar
• Alpay N, Sumnu A, Caliskan Y, Yazici H, Turkmen A, Gul A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int. 2010.
   Google Scholar
• Garcia-Gonzalez A, Weisman MH. The arthritis of familial Mediterranean fever. Semin Arthritis Rheum. 1992;22:139–50.
   PubMed Web of Science ®Google Scholar
• Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287:1302.
   PubMed Web of Science ®Google Scholar
• Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Col-chicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314:1001–5.
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Ozdogan H. Non-response to colchicine in FMF-definition, causes and suggested solutions. Clin Exp Rheumatol. 2008;26:549–51.
   Google Scholar
• Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonre-sponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004;33:273–82.
   PubMed Web of Science ®Google Scholar
• Tufan A, Babaoglu MO, Akdogan A, et al. Association of drug transporter gene AB CB 1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol. 2007;34:1540–4.
   PubMed Web of Science ®Google Scholar
• Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mecha-nisms of action and pitfalls. Immunotherapy. 2010;2:817–33.
   Google Scholar
• Baykal Y, Saglam K, Yilmaz MI, Taslipinar A, Akinci SB, Inal A. Serum sIL-2r, IL-6, IL-10 and TNF-alpha level in familial Mediterranean fever patients. Clin Rheumatol. 2003;22:99–101.
   PubMed Web of Science ®Google Scholar
• Gang N, Drenth JP, Langevitz P, et al. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol. 1999;26:890–7.
   PubMed Web of Science ®Google Scholar
• Yilmaz E, Balci B, Kutlay S, et al. Analysis of the modifying effects of SAA1, SAA2 and TNF-alpha gene polymorphisms on development of amyloidosis in FMF patients. Turk J Pediatr. 2003;45:198–202.
   PubMed Web of Science ®Google Scholar
• Celebi Kobak A, Kobak S, Kabasakal Y, Akarca US. Tumor necrosis factor-alpha gene promoter polymorphism in patients with familial Mediterranean fever. Clin Rheumatol. 2007;26:908–10.
   PubMed Web of Science ®Google Scholar
• Haddad JJ. The role of inflammatory cytokines and NF-kappaB/ MAPK signaling pathways in the evolution of familial Mediter-ranean fever: current clinical perspectives and potential thera-peutic approaches. Cell Immunol. 2009;260:6–13.
   PubMed Web of Science ®Google Scholar
• Papin S, Cazeneuve C, Duquesnoy P, Jeru I, Sahali D, Amselem S. The tumor necrosis factor alpha-dependent activation of the human meditenanean fever (MEFV) promoter is mediated by a synergistic interaction between C/EBP beta and NF kappaB p65. J Biol Chem. 2003;278:48839–47.
   PubMed Web of Science ®Google Scholar
• Ryan JG, Masters SL, Booty MG, et al. Clinical features and functional significance of the P3695/R408Q variant in pyrin, the familial Mediterranean fever protein. Ann Rheum Dis. 2010;69:1383–8.
   PubMed Web of Science ®Google Scholar
• Kasifoglu T, Calisir C, Cansu DU, Korkmaz C. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol. 2009;28:41–6.
   PubMed Web of Science ®Google Scholar
• Cinar M, Dine A, Simsek I, et al. The rate and significance of Mediterranean fever gene mutations in patients with ankylosing spondylitis: a three-month, longitudinal clinical study. Rheumatol Int. 2008;29:37–42.
   PubMed Web of Science ®Google Scholar
• Chae JJ, Wood G, Richard K, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood. 2008;112:1794–803.
   PubMed Web of Science ®Google Scholar
• Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine. 2008;75:504–5.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002;20:S1–13.
   PubMed Web of Science ®Google Scholar
• Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr. 2008;167:695–6.
   PubMed Web of Science ®Google Scholar
• Gattringer R, Lagler H, Gattringer KB, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest. 2007;37:912–4.
   PubMed Web of Science ®Google Scholar
• Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. Effective treat-ment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis. 2007;66:1545–6.
   PubMed Web of Science ®Google Scholar
• Hennig S, Bayegan K, Uffmann M, Thalhammer F, Winkler S. Pneumonia in a patient with familial Mediterranean fever suc-cessfully treated with anakinra-case report and review. Rheu-matol Int. 2010.
   Google Scholar
• Moser C, Pohl G, Haslinger I, et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant. 2009;24:676–8.
   PubMed Web of Science ®Google Scholar
• Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I. Interleukin-1 targeting drugs in familial Mediter-ranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011.
   Google Scholar
• Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis. 2011.
   Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-asso-ciated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58:2443–52.
   PubMed Web of Science ®Google Scholar